Matches in DBpedia 2016-04 for { ?s ?p "JNJ-26489112 is an anticonvulsant drug that was being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It was expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.JNJ-26489112 was also being studied as a treatment for major depressive disorder."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- JNJ-26489112 abstract "JNJ-26489112 is an anticonvulsant drug that was being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It was expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.JNJ-26489112 was also being studied as a treatment for major depressive disorder.".
- Q16997761 abstract "JNJ-26489112 is an anticonvulsant drug that was being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It was expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.JNJ-26489112 was also being studied as a treatment for major depressive disorder.".
- JNJ-26489112 comment "JNJ-26489112 is an anticonvulsant drug that was being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It was expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.JNJ-26489112 was also being studied as a treatment for major depressive disorder.".
- Q16997761 comment "JNJ-26489112 is an anticonvulsant drug that was being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It was expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.JNJ-26489112 was also being studied as a treatment for major depressive disorder.".